References
- Kritski AL, Rodrigues de Jesus LS, Andrade MK, Werneck-Barroso E, Vieira MA, Haffner A, et al. Retreatment tuberculosis cases: factors associated with drug resistance and adverse outcomes. Chest 1997;111:1162-7 https://doi.org/10.1378/chest.111.5.1162
- Bechan S, Connolly C, Short GM, Standing E, Wilkinson D. Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa. Trans R Soc Trop Med Hyg 1997;9 1:704-7
- Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32 https://doi.org/10.1056/NEJM199302253280802
- Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84 https://doi.org/10.1056/NEJM199404283301702
- Pearce SJ, Horne NW. Follow-up of patients with pulmonary tuberculosis adequately treated by chemotherapy:is this really necessary? Lancet 1974;2:641-3
- Singapore Tuberculosis Service/Birtish Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988;137:1147-50 https://doi.org/10.1164/ajrccm/137.5.1147
- Kopanoff DE, Snider DE Jr, Johnson M. Recurrent tuberculosis: why do patients develop disease again- Am J Public Health 1988;78:30-3 https://doi.org/10.2105/AJPH.78.1.30
- Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. Chest 1997;111:1168-73 https://doi.org/10.1378/chest.111.5.1168
- Jarvis B, Lamb HM. Rifapentine. Drugs 1998;56:607-16 https://doi.org/10.2165/00003495-199856040-00008
- Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979;76:741-3 https://doi.org/10.1378/chest.76.6_Supplement.741
- Davidson PT, Le HQ. Drug treatment of tuberculosis:1992. Drugs 1992;43:651-73 https://doi.org/10.2165/00003495-199243050-00003
- Kilpatrick GS. Compliance in relation to tuberculosis. Tubercle 1987;68:31-2 https://doi.org/10.1016/S0041-3879(87)80018-1
- Cueno WD, Snider DE Jr. Enhancing patient compliance with tuberculosis therapy. Clin Chest Med 1989;10:375-80
- Snider DE Jr, Roper WL. The new tuberculosis. N Engl J Med 1992;326:703-5 https://doi.org/10.1056/NEJM199203053261011
- Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999;3:273-80
- American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77
- Centers for Disease Control. Patients with recurrent tuberculosis. MMWR Morb Mortal Wkly Rep 1982;30:645-7
- la Raja M, Screm C, Talmassons G, Pasquadibisceglie A, Pitzalis G, Pitzus E. Antituberculosis drug-resistance surveillance as a tool for tuberculosis control programmes. Monaldi Arch Chest Dis 1997;52:450-4
- Strull GE, Dym H. Tuberculosis: diagnosis and treatment of resurgent disease. J Oral Maxillofac Surg 1995;53:1334-40 https://doi.org/10.1016/0278-2391(95)90597-9
- Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963;29:565-78
- Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004;8:361-8
- Kim HK, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001;5:1129-36
- Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000;355:1345-50 https://doi.org/10.1016/S0140-6736(00)02124-3
- Mangura B, Napoltano E, Pascannante M, Sarrel M, McDonald R, Galanowsky K, et al. Directly observed therapy(DOT) is not the entire answer: an operational cohort analysis. Int J Tuberc Lung Dis 2002;6:654-61
- Bernheim F. Effect of salicylates on oxygen uptake of tubercle bacillus. Science 1940;92:204
- Lehman J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946;250:15-6
- Lorian V. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins; 1986
- Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 2004;53:275-82 https://doi.org/10.1111/j.1365-2958.2004.04120.x
- Kucers A, Bennett N. The use of antibiotics. 3rd ed. London: Heinemann; 1979
- Pfuetze K, de la Huerga J, Frakis A. Out-patient acceptance of PAS: transactions of the 20th research conference in pulmonary diseases. Washington, DC:Veterans Administration Department of Medicine and Surgery; 1961
- Ormerod LP. Multidrug-resistant tuberculosis(MDR-T B): epidemiology, prevention and treatment. Br Med Bull 2005;73:17-24 https://doi.org/10.1093/bmb/ldh047